Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) represents a
distinct phenotype among solid tumors characterized by frequent frameshift mutations …

Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to
revolutionise the personalised management of colorectal cancer. For patients with early …

Mismatch repair deficiency (dMMR) is found in approximately 15% of non-metastatic colon
cancers (CCs) and is characterized by a defective DNA mismatch repair system, resulting in …

Simple Summary Immunotherapy has reshaped the prognosis of several tumor types. In
metastatic colorectal cancer, only tumors with microsatellite instability or mismatch repair …

PURPOSE The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a
pragmatic basket trial evaluating antitumor activity of approved targeted agents in patients …

PURPOSE We conducted a systematic review to evaluate the outcome of patients with early-
stage (stages I-III) mismatch repair deficient (dMMR) colorectal cancer (CRC) receiving …

Importance Colorectal cancers (CRCs) with deficient DNA mismatch repair (dMMR) account
for 15% of all CRCs. Deficient MMR is a predictive biomarker associated with …

Approximately 15% of locally advanced colorectal cancers (CRC) have DNA mismatch
repair deficiency (dMMR), resulting in high microsatellite instability and a high tumour …

Surgery with or without adjuvant chemotherapy is the standard treatment for early-stage
colon cancer. However, evidence has recently emerged for neoadjuvant chemotherapy, with …